Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment

Acta Tropica

Volumn 127, Issue 2, 2013, Pages 101-104

  Pérez Molina, José A ^a   Sojo Dorado, Jesús ^a   Norman, Francesca ^a   Monge Maillo, Begoña ^a   Díaz Menéndez, Marta ^a   Albajar Viñas, Pedro ^b   López Vélez, Rogelio ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Adverse events; Benznidazole; Chagas disease; Nifurtimox; Toxicity; Trypanosoma cruzi

Indexed keywords

BENZNIDAZOLE; NIFURTIMOX;

DISEASE TREATMENT; DRUG; HEALTH CARE; PUBLIC HEALTH; TOXICITY;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANOREXIA; ANXIETY; ARTHRALGIA; ARTICLE; ASYMPTOMATIC INFECTION; CHAGAS DISEASE; CLINICAL ARTICLE; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; LEUKOPENIA; LIVER TOXICITY; MACULOPAPULAR RASH; MALE; MYALGIA; NAUSEA; NEUROTOXICITY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; SENSORY NEUROPATHY; SIDE EFFECT; SWEATING; URTICARIA;

ADOLESCENT; ADULT; CHAGAS DISEASE; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; MALE; MIDDLE AGED; NIFURTIMOX; NITROIMIDAZOLES; TRYPANOCIDAL AGENTS; YOUNG ADULT;

TRYPANOSOMA CRUZI;

EID: 84877661272     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2013.04.003     Document Type: Article

References (17)

1. Andrade J.P., Marin-Neto J.A., Paola A.A., Vilas-Boas F., Oliveira G.M., Bacal F., Bocchi E.A., Almeida D.R., Fragata Filho A.A., Moreira Mda C., Xavier S.S., Oliveira Junior W.A., Dias J.C. I Latin American guidelines for the diagnosis and treatment of Chagas cardiomyopathy. Arq. Bras. Cardiol. 2011, 97:1-48.
2. Bern C., Montgomery S.P., Herwaldt B.L., Rassi A., Marin-Neto J.A., Dantas R.O., Maguire J.H., Acquatella H., Morillo C., Kirchhoff L.V., Gilman R.H., Reyes P.A., Salvatella R., Moore A.C. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 2007, 298:2171-2181.
3. Castro J.A., de Mecca M.M., Bartel L.C. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum. Exp. Toxicol. 2006, 25:471-479.
4. Coura J.R., Borges-Pereira J. Chronic phase of Chagas disease: why should it be treated? A comprehensive review. Mem. Inst. Oswaldo Cruz 2011, 106:641-645.
5. Common Terminology Criteria for Adverse Events (CTCAE), 2006. National Cancer Institute, US National Institutes of Health.
6. Gascon J., Albajar P., Canas E., Flores M., Gomez i Prat J., Herrera R.N., Lafuente C.A., Luciardi H.L., Moncayo A., Molina L., Munoz J., Puente S., Sanz G., Trevino B., Sergio-Salles X. Diagnosis, management and treatment of chronic Chagas' heart disease in areas where Trypanosoma cruzi infection is not endemic. Enferm. Infecc. Microbiol. Clin. 2008, 26:99-106.
7. Hasslocher-Moreno A.M., do Brasil P.E., de Sousa A.S., Xavier S.S., Chambela M.C., Sperandio da Silva G.M. Safety of benznidazole use in the treatment of chronic Chagas' disease. J. Antimicrob. Chemother. 2012, 67:1261-1266.
8. Jackson Y., Alirol E., Getaz L., Wolff H., Combescure C., Chappuis F. Tolerance and safety of nifurtimox in patients with chronic chagas disease. Clin. Infect. Dis. 2010, 51:e69-e75.
9. Perez-Ayala A., Perez-Molina J.A., Norman F., Navarro M., Monge-Maillo B., Diaz-Menendez M., Peris-Garcia J., Flores M., Canavate C., Lopez-Velez R. Chagas disease in Latin American migrants: a Spanish challenge. Clin. Microbiol. Infect. 2011, 17:1108-1113.
10. Perez-Molina J.A., Norman F., Lopez-Velez R. Chagas disease in non-endemic countries: epidemiology, clinical presentation and treatment. Curr. Infect. Dis. Rep. 2012, 14:263-274.
11. Pinazo M.J., Munoz J., Posada E., Lopez-Chejade P., Gallego M., Ayala E., Del Cacho E., Soy D., Gascon J. Tolerance of benznidazole in treatment of Chagas' disease in adults. Antimicrob. Agents Chemother. 2010, 54:4896-4899.
12. Raaflaub J., Ziegler W.H. Single-dose pharmacokinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung 1979, 29:1611-1614.
13. Rassi A., Amato Neto V., de Siqueira A.F., Ferriolli Filho F., Amato V.S., Rassi G.G., Rassi Junior A. Treatment of chronic Chagas' disease with an association of nifurtimox and corticoid. Rev. Soc. Bras. Med. Trop. 2002, 35:547-550.
14. Schmunis G.A., Yadon Z.E. Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop. 2010, 115:14-21.
15. Viotti R., Vigliano C., Lococo B., Alvarez M.G., Petti M., Bertocchi G., Armenti A. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev. Anti. Infect. Ther. 2009, 7:157-163.
16. Wilkinson S.R., Kelly J.M. Trypanocidal drugs: mechanisms, resistance and new targets. Expert Rev. Mol. Med. 2009, 11:e31.
17. Yun O., Lima M.A., Ellman T., Chambi W., Castillo S., Flevaud L., Roddy P., Parreno F., Albajar Vinas P., Palma P.P. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins Sans Frontieres. PLoS Negl. Trop. Dis. 2009, 3:e488.